Reuters logo
BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09
2017年11月13日 / 下午12点49分 / 9 天前

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

Nov 13 (Reuters) - Redhill Biopharma Ltd

* Redhill Biopharma reports 2017 third quarter financial results

* Q3 revenue $1.5 million

* Redhill Biopharma Ltd - ‍decrease quarterly cash burn rate and continued revenue growth are expected in 2018​

* Redhill Biopharma Ltd - ‍top-line results from first Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in mid-2018​

* Redhill Biopharma - ‍top-line results from confirmatory Phase III study with Talicia (RHB-105) for treatment of H. Pylori infection, expected in H2/2018​

* Redhill Biopharma Ltd qtrly ‍loss per ordinary share us$0.09​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below